Gramicidin A Mutants with Antibiotic Activity against Both Gram-Positive and Gram-Negative Bacteria

Antimicrobial peptides (AMPs) have shown potential as alternatives to traditional antibiotics for fighting infections caused by antibiotic‐resistant bacteria. One promising example of this is gramicidin A (gA). In its wild‐type sequence, gA is active by permeating the plasma membrane of Gram‐positive bacteria. However, gA is toxic to human red blood cells at similar concentrations to those required for it to exert its antimicrobial effects. Installing cationic side chains into gA has been shown to lower its hemolytic activity while maintaining the antimicrobial potency. In this study, we present the synthesis and the antibiotic activity of a new series of gA mutants that display cationic side chains. Specifically, by synthesizing alkylated lysine derivatives through reductive amination, we were able to create a broad selection of structures with varied activities towards Staphylococcus aureus and methicillin‐resistant S. aureus (MRSA). Importantly, some of the new mutants were observed to have an unprecedented activity towards important Gram‐negative pathogens, including Escherichia coli, Klebsiella pneumoniae and Psuedomonas aeruginosa. Fighting resistance! We report the synthesis and characterization of a series of novel gramicidin A (gA) mutants that display modified d‐Lys side chains. Selected mutants are found to be potent antibiotics against MRSA, as well as a number of Gram‐negative pathogens. The activity against Gram‐negative bacteria is unprecedented for gA‐based peptides.